The company developed the instrument using in-licensed technology coupled with its own chemistry and other technology for exosomal protein analysis.
With an initial focus on exosome biology, the technology giant is looking for ways to use the microfluidic chip, which can sort particles as small as 20 nanometers.
The partners have a long-standing sponsored research agreement focused on phosphatidylserine, a signaling molecule found in tumor exosomes.
The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.
The company plans to make the platform available to collaborators conducting research on exosomal biomarkers with the aim of development new diagnostics.
The method may allow for higher resolution analysis of liquid biopsy samples, and could be useful for monitoring and guiding treatment for cancer patients.
The new firm will be based in the Boston area and is co-founded by MD Anderson Professor Raghu Kalluri and Broad Institute Director Eric Lander.
The funds will support the commercial launch this year of a number of Exosome's liquid biopsy cancer tests, and the development of new assays for neurodevelopmental diseases.
In a 250-patient cohort, the marker detected pancreatic cancer stages I-IV with specificity and sensitivity of 100 percent.
Exosome will use the ALCMI samples to support the validation of its ALK and EGFR T790M liquid biopsy tests, which the company plans to launch this year as LDTs.
In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.
Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.
HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.
Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.